Join Dr Charles Pollack for a discussion of his cutting-edge study: Idarucizumab for Dabigatran Reversal — Full Cohort Analysis
Topic
While the preventative properties of NOACs for thrombotic events have been established, many clinicians have expressed reservations for use of NOACs due to the possibility of major bleeding. However, what if a safety net were available, enabling clinicians to administer NOACs more confidently? In this important Journal Club, Dr Charles Pollack will discuss the results of his recent study which show that the effects of the NOAC dabigatran, specifically the possibility of major bleeding, can be wholly and rapidly reversed by the monoclonal antibody idarucizumab.
Target audience
This educational activity is designed for cardiologists, surgeons, primary care physicians, GPs, nurses and any other healthcare professional with an interest or role in atrial fibrillation management.
Learning objective
After this activity, participants should be able to:
Funding
This independent educational activity by NOAC Education is supported by funding from Boehringer Ingelheim. PCM Scientific is the medical education company acting as scientific secretariat and organiser for this programme. The activity is run at arm’s length from the financial supporter and all content is created by the faculty. No funder has had input into the content of the activity.
